MA49452A - Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire - Google Patents

Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire

Info

Publication number
MA49452A
MA49452A MA049452A MA49452A MA49452A MA 49452 A MA49452 A MA 49452A MA 049452 A MA049452 A MA 049452A MA 49452 A MA49452 A MA 49452A MA 49452 A MA49452 A MA 49452A
Authority
MA
Morocco
Prior art keywords
systemic
pulmonary artery
shunt thrombosis
preventing shunt
preventing
Prior art date
Application number
MA049452A
Other languages
English (en)
Inventor
Thomas G Diacovo
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA49452A publication Critical patent/MA49452A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MA049452A 2017-06-23 2018-06-22 Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire MA49452A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762524102P 2017-06-23 2017-06-23

Publications (1)

Publication Number Publication Date
MA49452A true MA49452A (fr) 2021-05-05

Family

ID=62842064

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049452A MA49452A (fr) 2017-06-23 2018-06-22 Procédé de prévention de thrombose de shunt de l'artère systémique-pulmonaire

Country Status (9)

Country Link
US (3) US11260071B2 (fr)
EP (1) EP3641784B1 (fr)
KR (1) KR102768341B1 (fr)
CN (1) CN110740736A (fr)
BR (1) BR112019022676A2 (fr)
CA (1) CA3060345A1 (fr)
MA (1) MA49452A (fr)
MX (1) MX2019015448A (fr)
WO (1) WO2018234565A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012011298B1 (pt) * 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
WO2025068477A1 (fr) * 2023-09-29 2025-04-03 Fundació Institut De Recerca De L´Hospital De La Santa Creu I Sant Pau Nouvelle génération d'antithrombotiques ciblant lrp5

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US759316A (en) 1902-12-06 1904-05-10 Walter C Runge Telephone-receiver.
FR2530247B1 (fr) 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
KR100315612B1 (ko) 1993-02-10 2002-06-20 추후제출 N-알킬-2-치환아데노신트리포스페이트동족체
ID21635A (id) 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku
SE9702680D0 (sv) 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
SE9904377D0 (sv) 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
AU2001267916B2 (en) 2000-07-06 2004-09-09 Daiichi Sankyo Company, Limited Hydropyridine derivative acid addition salts
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US20020123791A1 (en) 2000-12-28 2002-09-05 Harrison William J. Stent design with increased vessel coverage
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
US7758630B2 (en) 2003-04-14 2010-07-20 Tryton Medical, Inc. Helical ostium support for treating vascular bifurcations
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
WO2005087266A1 (fr) 2004-03-05 2005-09-22 Vddi Pharmaceuticals Polytherapie bloquant l'agregation plaquettaire
US20080214599A1 (en) 2005-08-19 2008-09-04 John Thomas Brandt Use of Par-1/Par-4 Inhibitors for Treating or Preventing Vascular Diseases
DE102006020386A1 (de) 2006-04-28 2007-10-31 Dade Behring Marburg Gmbh Verfahren zur Bestimmung der Thrombozytenfunktion unter Flussbedingungen
WO2008006912A2 (fr) 2006-07-14 2008-01-17 Biocompatibles Uk Limited polymÈre
DE102006051625A1 (de) 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
EA020531B1 (ru) 2007-04-13 2014-11-28 Милленниум Фармасьютикалз, Инк. КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИКОАГУЛИРУЮЩЕГО СРЕДСТВА С СОЕДИНЕНИЕМ, КОТОРОЕ ДЕЙСТВУЕТ КАК ИНГИБИТОР ФАКТОРА Ха
JP5681485B2 (ja) 2007-04-27 2015-03-11 サイデックス・ファーマシューティカルズ・インコーポレイテッド クロピドグレルおよびスルホアルキルエーテルシクロデキストリンを含有する製剤ならびに使用方法
CA2686203A1 (fr) 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Dosage oral et intraveineux de l'inhibiteur p2y12 reversible et a action directe
US20090043380A1 (en) 2007-08-09 2009-02-12 Specialized Vascular Technologies, Inc. Coatings for promoting endothelization of medical devices
US8998978B2 (en) 2007-09-28 2015-04-07 Abbott Cardiovascular Systems Inc. Stent formed from bioerodible metal-bioceramic composite
US20110276123A1 (en) 2007-11-27 2011-11-10 Davies Peter F Vascular stent design
CA2623449C (fr) 2008-03-27 2010-11-02 Lance Baldo Nouvelle application de la bivalirudine dans le traitement d'un syndrome coronarien aigu
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
WO2009140092A1 (fr) * 2008-05-13 2009-11-19 The Medicines Company Conservation de l'inhibition de plaquettes durant une thérapie anti-plaquettes
US8680052B1 (en) 2013-03-09 2014-03-25 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
KR101138294B1 (ko) 2008-09-24 2012-04-25 김형일 혈관벽 임시 골격용 생분해성 블랜드
EP2488026A4 (fr) 2009-10-02 2013-04-10 Merck Sharp & Dohme Utilisation d'un antagoniste du par-1 en combinaison avec un antagoniste du récepteur de l'adp p2y12 pour l'inhibition de la thrombose
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
BR112012011298B1 (pt) 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
EP2563369A2 (fr) 2010-04-29 2013-03-06 Thrombologic APS Méthodes de traitement de patients présentant un risque accru de développer des événements ischémiques et composés associés
JP5947316B2 (ja) 2011-02-09 2016-07-06 ザ メディシンズ カンパニー 肺高血圧症を処置するための方法
CN103860459A (zh) 2012-12-11 2014-06-18 天津市汉康医药生物技术有限公司 一种坎格雷洛注射剂及其制备方法
EA034550B1 (ru) 2013-03-09 2020-02-19 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способы лечения, снижения частоты и/или профилактики ишемических событий
JPWO2016035780A1 (ja) 2014-09-02 2017-06-15 第一三共株式会社 ステント留置後の血栓・塞栓の形成を抑制するための医薬組成物
CN115990138A (zh) 2015-01-14 2023-04-21 奇斯药制品公司 包含高纯度坎格雷洛的药物制剂以及制备和使用它们的方法

Also Published As

Publication number Publication date
US20220117994A1 (en) 2022-04-21
KR20200018481A (ko) 2020-02-19
US11260071B2 (en) 2022-03-01
US12502400B2 (en) 2025-12-23
EP3641784B1 (fr) 2026-03-04
BR112019022676A2 (pt) 2020-05-19
US20200054662A1 (en) 2020-02-20
CA3060345A1 (fr) 2018-12-27
EP3641784A1 (fr) 2020-04-29
RU2019142647A3 (fr) 2021-11-29
WO2018234565A1 (fr) 2018-12-27
MX2019015448A (es) 2020-02-19
US20240342205A1 (en) 2024-10-17
CN110740736A (zh) 2020-01-31
KR102768341B1 (ko) 2025-02-18
RU2019142647A (ru) 2021-07-23

Similar Documents

Publication Publication Date Title
IL285151A (en) Methods of treating fgf21-associated disorders
MA52665A (fr) Procédé d'amélioration de l'expression de l'hémoglobine foetale
IL289423A (en) Compounds and methods for treating neurological and cardiovascular conditions
EP3733242C0 (fr) L'assurance qualité de radiothérapie
EP3294865A4 (fr) Procédés de production d'épimérases et d'alcaloïdes benzylisoquinoléine
EP3604513A4 (fr) Composition pour la production de tagatose et procédé de production de tagatose l'utilisant
EP3443094A4 (fr) Procédés de réduction de l'expression de c9orf72
FI4327866T3 (fi) Mirikitsumabi haavaisen paksusuolitulehduksen hoitoon
MA50169A (fr) Procédé de production d'un électrocatalyseur
IL260730B (en) Process for preparing terpinene-4-ol
EP3558312A4 (fr) Procédés d'amélioration de la densité vasculaire
EP3476800A4 (fr) Sel métallique de bis(fluorosulfonyl)imide et sa méthode de préparation
EP3589678C0 (fr) Procédé de préparation de polyéther carbonates
EP3568077A4 (fr) Procédé d'estimation de volume sanguin
EP3647316C0 (fr) Procédé de production d'édulcorant à base d'allulose
DK3331610T3 (da) Midler til anvendelse til behandling af gliom
IL284374A (en) Methods of producing ustekinumab
MA42423A (fr) Procédé de préparation d'un revêtement
SG11202010677XA (en) Methods for the production of methacrylates
IT201700093172A1 (it) Metodo per l'identificazione precoce di riacutizzazioni di broncopneumopatia cronica ostruttiva
EP3348278A4 (fr) Inhibiteur de la sécrétion d'exosomes
EP3612133A4 (fr) Échafaudages implantables pour le traitement de la sinusite
HUE063820T2 (hu) Módszerek kardiovaszkuláris betegségek kezelésére
DE112018004164A5 (de) Verfahren zur Wertbestimmung von Parametern
EP3549711A4 (fr) Procédé de réglage d'âme